Skip to main content
OpenTrials
Completed

NCT Number: NCT04978103

Effects of Gum Arabic on Metabolic Syndrome Parameters in Postmenopausal Women

Gum Arabic ingestion has been proved to decrease some of the inflammatory markers in some metabolic diseases that have an inflammatory background. Nevertheless, the mechanism/s by which it does so is uncertain. This study is targeting one of the postulated molecular mechanisms at genetic level that may help to understand how Gum Arabic exerts its effect .The effects of GA on Nuclear Factor Kappa Beta, P38 Mitogen Activated Protein (MAP) Kinase levels, and on the expression of inflammatory cytokines genes are going to be assessed in postmenopausal females with Metabolic Syndrome.

Completed

Looking for future studies?

Notify Me

Key information

Age range

45 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

University of Khartoum

Khartoum, 11111, Sudan

About this study

The Metabolic syndrome (MetS) is a collection of several interconnected biochemical, clinical, and metabolic factors that directly increase the risk of atherosclerotic cardiovascular disease and Diabetes Mellitus.

Hypertension, Dyslipidemia, insulin resistance, obesity, glucose intolerance, proinflammatory and prothrombotic states are the cornerstone features defining the syndrome. Glycerol, free fatty acids (FFA), tumor necrosis factor alpha (TNFα), interleukin 6 (IL6), interleukin 1(IL-1) and Interferon Gamma (INFγ) are some of the inflammatory substances (cytokines) that are released from different cells (monocytes and adipocytes) in MetS.

Gum Arabic is found as a mixture of sodium, calcium and potassium salts of branched polysaccharides. In the colon, GA is fermented by colonic bacteria into short chain fatty acids such as butyrate, which are partially absorbed into blood.

Butyrate treatment was found to inhibit expression of cytokine mRNAs in peripheral blood monocytes (PBMC) that are stimulated by bacterial lipopolysaccharide (LPS).

In unstimulated (PBMC), a transcription factor (Nuclear Factor kappa β (NF-κB)) controls gene expression of some inflammatory cytokines; Tumor Necrosis Factor Alpha (TNF- α), IL-1 and IL-6. NF-κB was detected mainly in the cytoplasm tightly bound to an Inhibitory protein (IκB).

When those cells are stimulated by bacterial lipopolysaccharide (LPS) or by adipokines, NFκB is activated and translocates to the nucleus to start gene expression of the inflammatory cytokines. Moreover; stimulation causes degradation of IκB which releases NFκB and allows its translocation to the nucleus.

This nuclear translocation of NFκB was found to be inhibited by butyrate (a byproduct of Gum Arabic fermentation ) providing evidence that butyrate mediated reduction of proinflammatory cytokines was achieved by reducing NFκB activation.

Consequently; the postulated mechanisms by which butyrate may regulate gene expression are through inhibition of NFκB activation and IκBα degradation.

NFκB and the inflammatory cytokines: Target for therapy in inflammatory diseases, are they?

As NFκB is involved in transcriptional regulation of many cytokines genes that contributes to immune and inflammatory responses, it may be a good target for therapy also. At present, treatment of inflammatory diseases depends greatly on aminosalicylates, corticosteroids, and immune-suppressants that decrease cytokines level especially TNF.

The anti-inflammatory and immune-modulatory properties of gum Arabic, through butyrate, described previously may offer an interesting alternative therapeutic approach for inflammatory conditions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Inclusion criteria Females Menopause Metabolic syndrome based on Adult panel II criteria Signed/verbal consent to participate

Exclusion criteria

  • Exclusion criteria
  • Patients with mental or physical disability
  • Use of corticosteroids or any other drug that affects body weight
  • History of Gum Arabic (GA) allergy
  • Chronicrenal or liver disease
  • Chronocinflammatory diseases
  • History of CVA or MI Participants will be asked to maintain their habitually daily diet and level of activity during the period of the study and to continue any previously prescribed medication.

Treatment and study plan

Gum Arabic

Drug

A dietary supplement (Powdered exudates of Acacia Senegal (Gum Arabic E-414))

Other names: Acacia Senegal

Primary outcomes

  1. Nuclear Factor Kappa Beta concentration in nanogram/dl

    Time frame: 12 weeks

    Nuclear regulatory protein

  2. P38 Mitogen activated protein kinase in nanogram/dl

    Time frame: 12 weeks

    Transcription regulatory protein

  3. Inhibitory Kappa Beta protein in nanogram/dl

    Time frame: 12 weeks

    inhibitory protein

  4. Tumor necrosis factor, interferon gamma and interleukin-6 in nanogram/dl

    Time frame: 12 weeks

    Proinflammatory cytokines

  5. Plasminogen activated protein inhibitor1 in picogram/dl

    Time frame: 12 weeks

    Protein Inhibitor

  6. Fasting Insulin in nanogram/dl

    Time frame: 12 weeks

    Metabolic hormone

  7. Insulin resistance by HOMA index

    Time frame: 12 weeks

    Measuring cells sensitivity to insulin

Secondary outcomes

  1. Fasting Blood Sugar in mg/dl

    Time frame: 12 weeks

    Biochemical serological markers

  2. Lipid profile in mg/dl

    Time frame: 12 weeks

    Serological markers

Other outcomes

  1. waist circumference in cm

    Time frame: 12 weeks

    Anthropometric measurement

Sponsors and collaborators

Lead sponsor

University of Khartoum

Other

Collaborators

  • Ministry of Higher Education and Scientific Research, Republic of Sudan

Registry information

Official study title

Effects of Gum Arabic Supplementation on the Components of Metabolic Syndrome Among Post Menopausal Females in Khartoum State 2019

Important dates

Study start
2019
Primary completion
2021
Study completion
2022
First posted
Jul 27, 2021
Registry last updated
Feb 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.